Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 31, 2005 Stephen D. Simpson	The DOJ Goes Fishing for Orthopedics The government's industry-wide investigation of orthopedics is more of a buying opportunity than a real threat.
The Motley Fool June 28, 2006 Stephen D. Simpson	Feds Once Again Knocking on Ortho Doors A second round of subpoenas rattles the medical device sector.
BusinessWeek May 30, 2005 Michael Arndt	BW 50: A Test Of Zimmer's Agility Artificial joint maker Zimmer Holdings Inc. has the lead in a hot business. But the company faces a Justice probe and price pressures.
The Motley Fool March 22, 2005 Stephen D. Simpson	Can Biomet Elbow the Competition? The No. 4 player in orthopedics looks to close the gap. No matter what valuation metric you want to look at, Biomet shares look expensive on an absolute basis.
The Motley Fool August 28, 2008 Brian Orelli	Stryker Strikes Back The orthopedics maker sues to stop a costly federal investigation.
The Motley Fool February 9, 2006 Stephen D. Simpson	Growth Not Enough for Smith & Nephew This orthopedic company has market-leading growth, but just not enough cash flow. Investors shouldn't get too excited about these shares.
Pharmaceutical Executive September 1, 2013 Shantanu Agrawal	Making Sense of the Sunshine Act: A New Era for Drug Promotion Now that the Sunshine Act's Open Payments spending disclosure program is live, the federal government's lead officer for compliance explains how the new web-based system will work and how US industry, providers, and patients will be better off by making their relationships fully transparent.
AskMen.com July 28, 2015 Tyson Lowrie	How To Tell If You Have A Bad Surgeon A new study by ProPublica, a patients' advocacy group, makes a damning claim: a relatively small number of surgeons are causing a disproportionate amount of complications, botched surgeries and occasionally deaths.
BusinessWeek November 12, 2007 Arlene Weintraub	Getting Hip to the Boomers Stryker's new orthopedic technology gives aging patients an alternative to full joint replacement.
The Motley Fool October 27, 2005 Stephen D. Simpson	Will Smith & Nephew Keep Flexing? This smaller, British, orthopedic company has competitive products, but industry trends could hurt it. However, the entire orthopedic sector is getting pretty interesting from a value perspective.
The Motley Fool September 21, 2005 Stephen D. Simpson	Can Biomet Stay Limber? Concerns about pricing have buffeted the orthopedic space and the No. 4 player in hips and knees. Whatever the case turns out to be, Biomet is probably a bit riskier than average.
BusinessWeek August 2, 2004 Michael Arndt	New Knees, No Big Deal Minimally invasive surgery uses smaller incisions, spares muscles and tendons, requires less medication, and gets patients up and out fast.
Pharmaceutical Executive March 1, 2009 Jill Wechsler	Through the Looking Glass Pharma relations with researchers are critical for developing new technology, and reformers will discourage inappropriate relationships by making any links to pharmaceutical marketing known to all.
The Motley Fool January 30, 2007 Ryan Fuhrmann	Zimmer Implants a New High Investors, the orthopedic designer, developer, and manufacturer isn't cheap, but stellar companies rarely are.
The Motley Fool October 25, 2007 Billy Fisher	Plenty of Strength in Zimmer Orthopedic manufacturer Zimmer Holdings reports a solid third quarter, but lowers its forecast for Q4.
The Motley Fool July 21, 2006 Stephen D. Simpson	Stryker and the Terror of the Unknown This has been a pretty bad year to be a good medical technology company. Fears about future pricing and the DOJ investigation keep a lid on the entire sector. So, what about that future for Stryker? Investors, take note.
The Motley Fool January 27, 2006 Stephen D. Simpson	Lightning Stryker The dust hasn't yet settled on the orthopedic sector, so wise investors should tread lightly with this medical technology company.
The Motley Fool July 26, 2007 Ryan Fuhrmann	Zimmer Simmers The maker of hip and knee replacements gets a leg up on the market. Investors, take note.
BusinessWeek March 31, 2011 David Voreacos et al.	Johnson & Johnson's Quality Catastrophe After 50-plus product recalls in 15 months, the $60 billion company is fighting to clear its once-trusted name.
Pharmaceutical Executive April 1, 2012	Special Section: Sunshine Act Still in the Shade Phase in of the Sunshine Act will force a reconsideration of the ethical consequences of all types of pharma meetings. How and to what extent remains to be seen.
The Motley Fool September 14, 2005 Stephen D. Simpson	Orthopedic Sector Stumbles Already antsy about potential pricing, investors reacted badly to British orthopedic company Smith & Nephew's earnings guidance.
The Motley Fool January 31, 2006 Stephen D. Simpson	Zimmer Muddles Through So long as the pressures in the orthopedic sector prove less than originally feared, investors could still make money here.
Pharmaceutical Executive October 1, 2010	Getting Ready for Sunshine Health reform requires detailed tracking and full disclosure of fees to docs for marketing and research.
BusinessWeek April 23, 2009 Catherine Arnst	Doctors' Pride: A Hurdle to Digital Medicine A forerunner in New England found that some physicians would sooner cut ties than see their elite status threatened.
The Motley Fool July 27, 2006 Stephen D. Simpson	Zimmer Provides Quarterly Information, and More In addition to its quarterly review, the orthopedic company gave some insight into the government probe. Investors, take note.
The Motley Fool October 17, 2008 Brian Orelli	Shareholders Slap Stryker A little earnings miss sends the medical technology company down more than necessary.
AskMen.com	Fake Study, Real Paycheck Medical device maker Medtronic paid about $850,000 over nearly 10 years to a former Army surgeon accused of forging signatures and falsifying data for a study touting the benefits of one of the company's implants.
The Motley Fool June 30, 2005 Stephen D. Simpson	Biomet Wants Your Body Steady growth continues at the #4 orthopedics player. But Biomet shares haven't had a great year so far, hovering close to their 52-week low.
BusinessWeek June 23, 2011 Drew Armstrong	The Simplest Rx: Check on Your Patient Doctors and insurers cut costs by sharing information.
CIO December 15, 2009 Kim S. Nash	Data Sharing That Benefits Customers At Children's Hospital Boston, sharing more data, securely, promises healthier, more satisfied patients.
CFO May 1, 2009 Josh Hyatt	Strong Medicine Boosted by a substantial injection of cash from the federal stimulus bill, electronic medical records may help relieve the pain of rising premiums by improving efficiencies in the medical system.
The Motley Fool December 12, 2006 Matthew Crews	Smith & Nephew, What's the Deal? A merger with Biomet would be good in many ways. But what's the right price? Investors, take note.
The Motley Fool July 27, 2006 Stephen D. Simpson	Smith & Nephew: Better Is Good Enough For British medical device company Smith & Nephew investors, better-than-expected is just fine.
The Motley Fool July 20, 2007 Ryan Fuhrmann	Stryker Does a Body Good The orthopedics company continues its double-digit growth in an industry with a bright future. Investors, take note.
The Motley Fool January 28, 2009 Brian Orelli	The Streak Is Over After 31 consecutive quarters of double-digit sales growth, medical device maker Stryker finally had an off quarter.
The Motley Fool April 26, 2005 Stephen D. Simpson	Growth Is Knee-High Zimmer turns in another fine quarter, with strength in knee implants leading the way.
The Motley Fool July 28, 2005 Stephen D. Simpson	Zimmer at a Simmer Strong demand for reconstructive products keeps this orthopedics company limber. Zimmer's 30-plus trailing price-to-earnings ratio still looks high, but it is in line with this industry's current multiples.
The Motley Fool April 28, 2004 Glen Trematore	Zimmer Makes a Family Proud Zimmer Holdings looks strong when compared with other orthopedic/medical device makers.
The Motley Fool October 18, 2007 Billy Fisher	An Empire Strykes Back Stryker reports a quarter of double-digit growth in revenue and earnings. Investors, take note.
The Motley Fool February 1, 2005 Stephen D. Simpson	Zimmer Shoots From the Hip Pure-play orthopedic company delivers the goods, but at what cost? Zimmer carries a price tag that would make a value investor's bones ache.
BusinessWeek November 12, 2009 Catherine Arnst	10 Ways to Cut Health-Care Costs Right Now Employers and hospitals don't have to wait for Congress to address inefficiencies and waste.
BusinessWeek December 6, 2004 Kathleen Kerwin	Knees And Hips -- And Now What? Stryker may need more than artificial joints. Its CEO-to-be is betting on biotech.
The Motley Fool August 27, 2010 Brian Orelli	A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much.
The Motley Fool July 18, 2008 Brian Orelli	What Strikes Against Stryker? High growth isn't enough to impress investors.
Commercial Investment Real Estate Sep/Oct 2009 Andrew Dick	Deal Diagnosis Healthcare real estate transactions not only are driven by economic factors, but also by compliance with federal and state healthcare laws.
The Motley Fool July 23, 2009 Robert Steyer	Long Convalescence for Device Makers Orthopedic product specialists Stryker and Zimmer Holdings forecast a slow-motion recovery.
Pharmaceutical Executive March 1, 2013 Al Topin	Less Selling, More Time What can happen when pharmaceutical reps focus on the physician-patient conversation?
Managed Care May 2007	Compensation Monitor Most docs break bread with pharma.
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
BusinessWeek January 7, 2010 Catherine Arnst	Hospitals: Radical Cost Surgery A hospital that slashes costs - and delivers high-quality care as it innovates? Yes, it exists.